Healthcare | January 05, 2023
Viatris acquires Oyster Point Pharma and Famy Life Sciences
Acquisitions have the potential to add at least $1 billion in sales by 2028
Acquisitions have the potential to add at least $1 billion in sales by 2028
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Having a healthy gut is key as it permits the body to build a stronger immune system
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
Subscribe To Our Newsletter & Stay Updated
